Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 5018 results found since Jan 2013.

Ublituximab for the treatment of CD20 positive B-cell malignancies.
Authors: Babiker HM, Glode AE, Cooke LS, Mahadevan D Abstract INTRODUCTION: Non-Hodgkin lymphoma (NHL) is the most common adult hematologic malignancy. Conventional methods of treatment are chemotherapy and radiation, which were associated with toxicities and lack of specificity. Potential cell surface targets for treatment of B-cell NHL (B-NHL) include CD19, CD20, and CD22 which are highly expressed on malignant B-cells. The development of monoclonal antibody (mAb) therapy directed against CD20 had the most clinical impact in the treatment of B-NHL. Early clinical trials with rituximab (RTX), the first chimeric mA...
Source: Expert Opinion on Investigational Drugs - April 5, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: A systematic review of trials
In this study, we performed a systematic review of all targeted therapies under clinical development in SLE in 17 online registries of clinical trials. The search yielded a total of 1140 trials, from which we identified 74 targeted therapies for SLE. Those treatments target inflammatory cytokines, chemokines, or their receptors (n = 17), B cells (n = 15), intracellular signalling pathways (n = 10), T/B cells costimulation molecules (n = 8), interferons (n = 7), plasmacytoid dendritic cells (pDC) (n = 3), plasma cells (n = 2), as well as various other targets (n = 12). Not all these candidate...
Source: Autoimmunity Reviews - June 7, 2018 Category: Allergy & Immunology Source Type: research

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials
In this study, we performed a systematic review of all targeted therapies under clinical development in SLE in 17 online registries of clinical trials. The search yielded a total of 1140 trials, from which we identified 74 targeted therapies for SLE. Those treatments target inflammatory cytokines, chemokines, or their receptors (n = 17), B cells or plasma cells (n = 17), intracellular signalling pathways (n = 10), T/B cells costimulation molecules (n = 8), interferons (n = 7), plasmacytoid dendritic cells (pDC) (n = 3), as well as various other targets (n = 12). Not all these candidate drugs wil...
Source: Autoimmunity Reviews - July 5, 2018 Category: Allergy & Immunology Source Type: research

What is the optimal initial management of the younger mantle cell lymphoma patient?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Rory McCulloch, Simon RuleAbstractThe last 20 years has seen considerable advances made in the management of younger patients with mantle cell lymphoma. The use of high dose cytarabine and rituximab in induction therapy, usually followed by autologous stem cell transplant consolidation, has become established practice and the median overall survival now exceeds 10 years. However, this high intensity upfront approach is not necessarily appropriate for all newly diagnosed patients. A minority exhibit disease that b...
Source: Best Practice and Research Clinical Haematology - July 5, 2018 Category: Hematology Source Type: research

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials
In this study, we performed a systematic review of all targeted therapies under clinical development in SLE in 17 online registries of clinical trials. The search yielded a total of 1140 trials, from which we identified 74 targeted therapies for SLE. Those treatments target inflammatory cytokines, chemokines, or their receptors (n = 17), B cells or plasma cells (n = 17), intracellular signalling pathways (n = 10), T/B cells costimulation molecules (n = 8), interferons (n = 7), plasmacytoid dendritic cells (pDC) (n = 3), as well as various other targets (n = 12). Not all these candidate drugs wil...
Source: Autoimmunity Reviews - July 10, 2018 Category: Allergy & Immunology Source Type: research

What is the optimal initial management of the younger mantle cell lymphoma patient?
Publication date: March 2018Source: Best Practice & Research Clinical Haematology, Volume 31, Issue 1Author(s): Rory McCulloch, Simon RuleAbstractThe last 20 years has seen considerable advances made in the management of younger patients with mantle cell lymphoma. The use of high dose cytarabine and rituximab in induction therapy, usually followed by autologous stem cell transplant consolidation, has become established practice and the median overall survival now exceeds 10 years. However, this high intensity upfront approach is not necessarily appropriate for all newly diagnosed patients. A minority exhibit disease that b...
Source: Best Practice and Research Clinical Haematology - July 10, 2018 Category: Hematology Source Type: research

The Diagnosis and Treatment of Primary CNS Lymphoma.
CONCLUSION: Current recommendations for the treatment of primary CNS lymphomaare based on only a small number of prospective clinical trials. Patients with this disease should be treated by interdisciplinary teams in experienced centers, andpreferably as part of a controlled trial. PMID: 29999484 [PubMed - in process]
Source: Deutsches Arzteblatt International - July 13, 2018 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis
ConclusionsThe discontinuation rates reported for non-anti-TNF drugs varied relative to the study design in which they were investigated. Regulatory agencies, price-setting entities, and evidence-gathering researchers should consider the effect of the real-life environment in their decisions and conclusions.
Source: European Journal of Clinical Pharmacology - July 18, 2018 Category: Drugs & Pharmacology Source Type: research

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
AbstractThe clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine –human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A second generation of anti-CD20 mAbs has been designed to be more effective, better tolerated, and of lower immunogenicity. These include the humanized versions: ocrelizumab, obinutuzumab, and v eltuzumab, and the fully human, ofatumumab. We conducted a literature ...
Source: Autoimmunity Highlights - November 16, 2017 Category: Allergy & Immunology Source Type: research

Severe Coombs Positive Autoimmune Hemolytic Anemia after Alemtuzumab Infusion for Relapsing Remitting Multiple Sclerosis. What Can We Learn?
Conclusion: Severe coombs positive AIHA is a rare life-threatening complication that can occur after Alemtuzumab infusion for RRMS. It can be rapidly progressive, intravascular, severe (hemoglobin frequently reaching to <5gm/dl) and frequently refractory to steroids. It usually occurs between 3-15 months after the Alemtuzumab infusion and can be fatal (with 1 reported death so far). Higher level of awareness is needed by the consulting hematologists of such a rare serious adverse effect that can occur specifically few months after Alemtuzumab infusion and calls for a closer monitoring of patient's hematological status d...
Source: Blood - November 21, 2018 Category: Hematology Authors: Desai, P. A., Romere, C. M., Nguyen, L., Saksena, A., Abdullah, S. J., Diaz, A. E. Tags: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II Source Type: research

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure
ConclusionThere is limited data on how patients with DLBCL involving the GI tract initially present and respond to therapy. This study encompassing almost twenty years of experience at a single institution, suggests that though patients present at all stages and as low risk vs high risk IPI, outcomes are poor compared to prior studies, especially when additional extranodal sites are involved. Duration of response can be substantial, however relapses are common and may present years later indicating ongoing follow-up is imperative.Figure 1.DisclosuresPortell: AbbVie: Research Funding; Amgen: Consultancy; Kite: Research Fund...
Source: Blood - November 21, 2018 Category: Hematology Authors: Arora, P. C., Orellana-Noia, V. M., Alfaraj, A., Christopher, W., Monson, S., Petroni, G., Portell, C. A., Williams, M. E. Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster II Source Type: research

Under-Reporting of Patient Reported Outcome (PRO) in Clinical Trials
Conclusions: Despite a growing emphasis on QOL and use of PROs in oncology clinical trials, and despite patient and health provider efforts to record PRO data, most CLL and NHL randomized trials still do not report the PRO endpoints. In several cases they were published later and in a partial manner, minimizing their impact on treatment decisions. This may indicate a disregard to PRO data collected, incomplete collection or methodological flaws in data analysis. Regardless of the reason, PRO data should be routinely included in study publications to allow for a complete assessment of investigational treatment outcome - inc...
Source: Blood - November 21, 2018 Category: Hematology Authors: Vidal-Fisher, L., Curtis, K. K., Vidal, L., Moss, K. R. Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research

Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies
Conclusion: Aurora kinase inhibitors are able to specifically and strongly enhance expression of CD20 antigen on the surface of immunotherapy-resistant cells and thereby they strongly sensitize cells to further treatment with CD20 mAbs. These inhibitors thus seem as suitable candidates for combination therapy together with CD20 antibodies.This research has been financially supported by the Ministry of Education, Youth and Sports of the Czech Republic under the project CEITEC 2020 (LQ1601) and by the research grant AZV-MZ-CR 15-33561AA-4/2015 and grant MUNI/A/0968/2017.DisclosuresDoubek: Janssen: Consultancy, Honoraria; Roc...
Source: Blood - November 21, 2018 Category: Hematology Authors: Kozlova, V., Ledererova, A., Doubek, M., Mayer, J., Pospisilova, S., Smida, M. Tags: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research

Risk Factors of Clostridium Difficile Infection in Hematopoietic Stem Cell Transplant Recipients: A Systemic Review and Meta-Analysis
Conclusion:HSCT recipients are at an increased risk of CDI compared to general population. In addition to the common risk factors like cephalosporin use and prior hospitalization, these patients have novel characteristics including presence of GVHD and cord blood transplant that puts them at a higher risk of CDI. HSCT patients with these risk factors may warrant a closer surveillance for early detection and treatment of CDI.Table 1.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Tariq, R., Furqan, F., Jamshed, S., Khanna, S. Tags: 901. Health Services Research-Non-Malignant Conditions: Poster III Source Type: research

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation
Conclusions: Approximately 15% of FL pts could currently achieve a very prolonged remission of about 10 years, even after multiple relapses. Its duration was 5x that of the last treatment line and more than twice that of active lymphoma, strongly suggesting the possibility of having achieved lymphoma cure. Younger age and grade 1-2 FL histology at diagnosis, and FLIPI low risk at relapse favored the achievement of PC-FL status. No specific treatment was associated with PC-FL and even an early relapse after first line treatment did not preclude to reach PC-FL, although early ASCT may be more effective for POD24 patients. Wh...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ferrari, S., Tucci, A., Valimberti, G., Anastasia, A., Bottelli, C., Petulla, M., Motta, M., Passi, A., Rossi, G. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies Source Type: research